Galectin Therapeutics's total assets for Q3 2024 were $28.97M, an increase of 4.76% from the previous quarter. GALT total liabilities were $121.45M for the fiscal quarter, a 10.61% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.